GSK collaborates with Cloud Pharmaceuticals

By collaborating with Cloud Pharmaceuticals, GSK will be set to apply Artificial Intelligence technology to improve their drug discovery efforts.
Cloud Pharmaceutical uses its technology to accelerate the drug discovery and design process by using an Artificial Intelligence driven process to deliver tailored drug target characteristics.
The collaboration compliments GSK’s ExScientia deal last year.

CEO of cloud Pharmaceuticals, Ed Addison commented on the collaboration, “The application of our technology has proven to shorten the time from target validation to lead molecule fairly dramatically. We believe that this agreement validates the strength of the process and reinforces the value we can offer in discovering novel, high-quality drug candidates.”